EPM2A Peptide

CAT: 0013-GTR18912810Size: 0.05 mgDry Ice: NoHazardous: No

1 / 1

CAT#:0013-GTR18912810Size:0.05 mg

Selected

24/48H Stock Items & 2 to 6 Weeks non Stock Items.

Quick Request Actions

Description

EPM2A Peptide

Product Name Alternative

EPM2, MELF, Laforin, Lafora PTPase, LAFPTPase

UniProt

O95278

Field of Research

Signal Transduction

Concentration

200 μg/mL

Form

Liquid

Storage Conditions

Store EPM2A peptide at -20°C, stable for one year.

Notes

For research use only.

Applications Notes

EPM2A peptide is used for blocking the activity of EPM2A antibody.

Tested Applications

Blocking

NCBI Accession Number

NP_005661

Preservative

PBS pH 7.2 (10 mM NaH2PO4, 10 mM Na2HPO4, 130 mM NaCl) containing 0.1% bovine serum albumin and 0.02% sodium azide

Related Products

Catalog	Name
GTR18975322	EPM2A Antibody Blocking peptide
GTR18975321	EPM2A Antibody Blocking peptide
GTR18986678	EPM2A (laforin) IP1 Immunizing Peptide
GTR18241420-01	EPM2A Antibody
GTR18079223	EPM2A Antibody
GTR18120346-01	EPM2A Antibody
GTR18582883-01	EPM2A Antibody
GTR17905258-01	EPM2A Antibody
GTR18206841-01	EPM2A Antibody
GTR18123732	EPM2A Antibody

Catalog	Name
MBS152586-01	EPM2A Peptide
abx269614	EPM2A (Laforin) Peptide
MBS428429-01	EPM2A (laforin) IP1 Immunizing Peptide
MBS3240894-01	EPM2A Peptide - N-terminal region
AAP63377-100UG	EPM2A Peptide - N-terminal region (AAP63377)
MBS9220873-01	EPM2A Antibody (C-term) Blocking Peptide
AAP63376-100UG	EPM2A Peptide - N-terminal region (AAP63376)
148856	EPM2A, Control Peptide (Laforin, Lafora PTPase, LAFPTPase, EPM2)
AB-23036-P	Human epilepsy, progressive myoclonus type 2A (EPM2A) Control/blocking peptide
E3384-75D-P	Epilepsy, Progressive Myoclonus Type 2A (Lafora Disease, EPM2A, Laforin, LD, LDE, EPM2, MELF, LAFPTPase, FLJ11207, KIAA0766) (Control Peptide) discontinued